To date, IDH1 and IDH2 inhibitors have been approved in acute myeloid leukemia and more recently in cholangiocarcinoma; nevertheless some clinical trials for other solid tumors with evidence of IDH1/2 mutations, including mCRC, are ongoing. Here, IDH2 is linked to cholangiocarcinoma.